GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » Forward PE Ratio

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Forward PE Ratio : 0.00 (As of Jun. 09, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals Forward PE Ratio?

Hepion Pharmaceuticals's Forward PE Ratio for today is 0.00.

Hepion Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Hepion Pharmaceuticals's PE Ratio for today is 0.00.


Hepion Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Hepion Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hepion Pharmaceuticals Forward PE Ratio Chart

Hepion Pharmaceuticals Annual Data
Trend
Forward PE Ratio

Hepion Pharmaceuticals Quarterly Data
Forward PE Ratio

Competitive Comparison of Hepion Pharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Hepion Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hepion Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's Forward PE Ratio falls into.



Hepion Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Hepion Pharmaceuticals  (NAS:HEPA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Hepion Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Executives
Peter Wijngaard director 8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster officer: Chief Scientific Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan officer: Chief Financial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: CEO and President
Donald E Garlikov 10 percent owner 41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson director
Thomas Phd Adams director
Gabriel Cerrone 10 percent owner VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai officer: Chief Medical Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein director, officer: Chief Executive Officer 1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa director C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung officer: Chief Financial Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Headlines

From GuruFocus

Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding

By Stock market mentor Stock market mentor 01-09-2023